241 related articles for article (PubMed ID: 36821067)
21. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Watanabe Y; Ogawa M; Tamura Y; Suda S; Kaneko M; Kumagawa M; Hirayama M; Matsumoto N; Yamamoto T; Moriyama M
J Investig Med High Impact Case Rep; 2021; 9():23247096211058489. PubMed ID: 34845921
[TBL] [Abstract][Full Text] [Related]
22. Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis.
Fukunaga A; Takata K; Itoh S; Yamauchi R; Tanaka T; Yokoyama K; Shakado S; Kohashi K; Yoshizumi T; Hirai F
Clin J Gastroenterol; 2023 Apr; 16(2):224-228. PubMed ID: 36495383
[TBL] [Abstract][Full Text] [Related]
23. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort.
Jost-Brinkmann F; Demir M; Wree A; Luedde T; Loosen SH; Müller T; Tacke F; Roderburg C; Mohr R
Aliment Pharmacol Ther; 2023 Jun; 57(11):1313-1325. PubMed ID: 36883351
[TBL] [Abstract][Full Text] [Related]
24. Two cases of severe oral mucositis caused by atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma.
Shimoji Y; Yamauchi R; Shibata K; Fukuda H; Fukunaga A; Tanaka T; Takata K; Yokoyama K; Shakado S; Hirai F
Clin J Gastroenterol; 2024 Jun; 17(3):523-529. PubMed ID: 38512635
[TBL] [Abstract][Full Text] [Related]
25. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
[TBL] [Abstract][Full Text] [Related]
26. A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma.
Iwasaki S; Hidaka H; Uojima H; Hashimura M; Nabeta T; Sanoyama I; Wada N; Kubota K; Nakazawa T; Shibuya A; Koizumi W
Clin J Gastroenterol; 2021 Aug; 14(4):1233-1239. PubMed ID: 34024039
[TBL] [Abstract][Full Text] [Related]
27. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
Liu G; Zhou W; Li X; Guo L; He T; Zhao J; Gong L
Front Immunol; 2021; 12():712351. PubMed ID: 34504494
[TBL] [Abstract][Full Text] [Related]
28. Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports.
Yeom KM; Song YG; Yoo JJ; Kim SG; Kim YS
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256417
[No Abstract] [Full Text] [Related]
29. An update on atezolizumab for hepatocellular carcinoma.
Ielasi L; Sansone V; Forgione A; Granito A; Benevento F; Tovoli F
Drugs Today (Barc); 2021 Jun; 57(6):365-375. PubMed ID: 34151903
[TBL] [Abstract][Full Text] [Related]
30. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
[TBL] [Abstract][Full Text] [Related]
31. Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.
Komatsu S; Fujishima Y; Kido M; Kuramitsu K; Goto T; Yanagimoto H; Toyama H; Fukumoto T
BMC Gastroenterol; 2021 Dec; 21(1):470. PubMed ID: 34911458
[TBL] [Abstract][Full Text] [Related]
32. [A Case of Multiple Postoperative Recurrence of Hepatocellular Carcinoma Successfully Treated with Atezolizumab plus Bevacizumab].
Fujii J; Shinke G; Takeda Y; Ohmura Y; Katsura Y; Kinoshita M; Aoyama S; Kihara Y; Katsuyama S; Ikeshima R; Hiraki M; Sugimura K; Masuzawa T; Hata T; Murata K
Gan To Kagaku Ryoho; 2023 Jan; 50(1):96-98. PubMed ID: 36759998
[TBL] [Abstract][Full Text] [Related]
33. Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.
Vithayathil M; D'Alessio A; Fulgenzi CAM; Nishida N; Schönlein M; von Felden J; Schulze K; Wege H; Saeed A; Wietharn B; Hildebrand H; Wu L; Ang C; Marron TU; Weinmann A; Galle PR; Bettinger D; Bengsch B; Vogel A; Balcar L; Scheiner B; Lee PC; Huang YH; Amara S; Muzaffar M; Naqash AR; Cammarota A; Personeni N; Pressiani T; Pinter M; Cortellini A; Kudo M; Rimassa L; Pinato DJ; Sharma R
Liver Int; 2022 Nov; 42(11):2538-2547. PubMed ID: 35986902
[TBL] [Abstract][Full Text] [Related]
34. Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature.
Singh B; Kaur P; Maroules M
J Investig Med High Impact Case Rep; 2021; 9():2324709621992207. PubMed ID: 33787380
[TBL] [Abstract][Full Text] [Related]
35. Polymyalgia rheumatica during combination therapy with atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.
Dosoden N; Kuzuya T; Ito Y; Nishino J; Ohno E; Kawabe N; Hashimoto S; Hirooka Y; Yasuoka H
Clin J Gastroenterol; 2023 Aug; 16(4):567-571. PubMed ID: 37071371
[TBL] [Abstract][Full Text] [Related]
36. [A Case of Successful Treatment of Recurrent Peritoneal Dissemination of Hepatocellular Carcinoma with Atezolizumab plus Bevacizumab Combination Therapy].
Katsura Y; Takeda Y; Ohmura Y; Sakamoto T; Shinke G; Katsuyama S; Ikeshima R; Kawai K; Hiraki M; Sugimura K; Masuzawa T; Takeno A; Hata T; Murata K
Gan To Kagaku Ryoho; 2021 Dec; 48(13):2027-2029. PubMed ID: 35045482
[TBL] [Abstract][Full Text] [Related]
37. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Cheng AL; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Ma N; Nicholas A; Wang Y; Li L; Zhu AX; Finn RS
J Hepatol; 2022 Apr; 76(4):862-873. PubMed ID: 34902530
[TBL] [Abstract][Full Text] [Related]
38. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.
Hack SP; Spahn J; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Yopp A; Chow P; Qin S
Future Oncol; 2020 May; 16(15):975-989. PubMed ID: 32352320
[TBL] [Abstract][Full Text] [Related]
39. A case of HCC successfully treated with infliximab-steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy.
Hagiwara S; Komeda Y; Nishida N; Yoshida A; Kudo M
Cancer Rep (Hoboken); 2022 Nov; 5(11):e1721. PubMed ID: 36224043
[TBL] [Abstract][Full Text] [Related]
40. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
